Category: vaccination

  • MIL-OSI New Zealand: Patient-focused New Zealand Health Plan tabled

    Source: New Zealand Government

    Health New Zealand’s New Zealand Health Plan was presented to Parliament this morning.

    Developed by Health New Zealand, the plan is a requirement under the Pae Ora (Healthy Futures) Act 2022. 

    “The plan outlines how Health New Zealand will deliver on the Government’s health priorities over the period 2024–2027,” Health Minister Simeon Brown says. 

    “It sets the direction for how we will improve health outcomes and ensure all New Zealanders can access the care they need, where and when they need it. 

    “It gives effect to the Government Policy Statement on Health 2024–2027, with a clear focus on the Government’s five health targets and five mental health targets:  

    Health targets: 

    faster cancer treatment
    improved childhood immunisation
    shorter stays in emergency departments
    shorter wait times for first specialist assessments
    shorter wait times for elective treatment.

    Mental health and addiction targets:

    faster access to specialist mental health and addiction services
    faster access to primary mental health and addiction services
    shorter mental health and addiction related stays in emergency departments
    increased mental health and addiction workforce development
    strengthened focus on prevention and early intervention.

    “The plan is focused on achieving the Government’s health targets, ensuring the health system delivers real results for patients and communities. These targets are backed by clear accountability and transparent reporting, so the public can track progress on a regular basis. 

    “Reducing wait times is a key priority for the Government. Too many New Zealanders have been left waiting far too long for the care they need. Under the last Government, waitlists ballooned – with the number of Kiwis waiting more than four months for elective procedures like hip, knee, or cataract surgeries increasing by over 2,500 per cent. 

    “Health New Zealand is focussed on delivering the Elective Boost programme, which will deliver 21,000 additional procedures over the 2025/2026 year to help clear the backlog of patients needing care.”

    The plan also sets out how the Government will grow and support the health workforce; improve clinical leadership with continuous quality improvement and innovation; invest in essential hospital infrastructure; ensure services are delivered more consistently across the country; and strengthen primary care across New Zealand so that people can receive timely, quality care in the community. 

    “Our focus is clear: putting patients back at the centre of the health system. We’re building a system that delivers real results, and this plan is a key part of that,” Mr Brown says.  

    MIL OSI New Zealand News

  • Lok Sabha to take up Goa ST representation bill and Merchant shipping bill

    Source: Government of India

    Source: Government of India (4)

    The Parliament has a list of important businesses for Friday, which includes The Readjustment of Representation of Scheduled Tribes in Assembly Constituencies of the State of Goa Bill, 2024, and ‘The Merchant Shipping Bill, 2024’.

    According to the list of business in the Lok Sabha, the bills will be moved for passage. The House also has private members’ business.

    Minister Prataprao Jadhav will make a statement regarding the status of implementation of the recommendations contained in the 137th and 150th reports of the Standing Committee on Health and Family Welfare on Vaccine Development, Distribution Management and Mitigation of Pandemic Covid-19 pertaining to the Ministry of Health and Family Welfare

    The Lok Sabha will take up the ‘The Readjustment of Representation of Scheduled Tribes in Assembly Constituencies of the State of Goa Bill, 2024’ for further consideration.

    The bill was introduced by the Union Law Minister, Arjun Ram Meghwal, on December 17, 2024.

    The bill aims to enable reservation of seats in accordance with Article 332 of the Constitution for effective democratic participation of members of Scheduled Tribes and to provide for the readjustment of seats in the Legislative Assembly of the State of Goa, in so far as such readjustment is necessitated by inclusion of certain communities in the list of the Scheduled Tribes in the State of Goa, according to the list of business in Lok Sabha.

    Minister of Ports, Shipping, and Waterways Sarbananda Sonowal will move ‘The Merchant Shipping Bill, 2024’ to update and unify existing law to align with international maritime treaties.

    The legislation will consolidate the law relating to ports, promote integrated port development, facilitate ease of doing business and ensure the optimum utilisation of India’s coastline; establish and empower State Maritime Boards for effective management of ports other than major ports; establish the Maritime State Development Council for fostering structured growth and development of the port sector; provide for the management of pollution, disaster, emergencies, security, safety, navigation, and data at ports; ensure compliance with India’s obligations under international instruments to which it is a party; take measures for the conservation of ports; provide for adjudicatory mechanisms for the redressal of port-related disputes. The Bill will be tabled for consideration and passage.

    In the Rajya Sabha, seven ministers will lay papers on the table concerning their ministries.

    The House will also see statements made by two Ministers.

    Union Minister of State for Communications and Rural Development Dr Pemmasani Chandra Sekha will make the following statements regarding: (a) Status of implementation of the Recommendations contained in the 2nd Report of the Department-related Parliamentary Standing Committee on Rural Development and Panchayati Raj (18th Lok Sabha) on Demands for Grants (2024-25) pertaining to the Ministry of Rural Development (Department of Land Resources).

    (b) Status of implementation of the Recommendations contained in the 6th Report of the Department-related Parliamentary Standing Committee on Rural Development and Panchayati Raj (18th Lok Sabha) on Demands for Grants (2025-26) pertaining to the Ministry of Rural Development (Department of Land Resources).

    Union Minister of State for Railways and Food Processing Industries Ravneet Singh Bittu will make a statement regarding the Status of implementation of Recommendations/Observations contained in the 3rd Report of the Department-related Parliamentary Standing Committee on Railways(18th Lok Sabha) on Demands for Grants (2025-26) about the Ministry of Railways.

    (IANS)

  • MIL-OSI Africa: Free State government urges parents to vaccinate children

    Source: Government of South Africa

    Friday, August 1, 2025

    As part of ongoing efforts to prevent the further spread of measles, the Free State Department of Health has called on parents and guardians to ensure that they and their children are up to date with their vaccinations, in accordance with the provisions of the Road to Health Booklet.

    The department reported 93 laboratory confirmed cases of measles as of week 29 in the Lejweleputswa District.

    “Since the first positive case was detected in the private health sector on 23 February 2025, the department has taken decisive action to control the outbreak. The initial cases in Lejweleputswa were followed by a series of confirmed cases, with the most affected sub-district being Matjhabeng, which accounts for 42 of the total cases. 

    “The Nala area has also seen an increase in cases, necessitating continued vigilance and response efforts,” the department said on Thursday.

    The department reported that the outbreak in Mangaung has been declared over, which it described as a testament to the effectiveness of the outbreak response measures. 

    In Lejweleputswa, while sporadic cases have been observed from weeks 20 to 29, the department said the outbreak is under control. 

    The focus remains on the areas with higher numbers of unvaccinated individuals, particularly in Matjhabeng and Nala.

    “The department urges all residents to remain vigilant, particularly in areas with higher case numbers. The Free State Department of Health is dedicated to protecting the health of communities and will continue to monitor the situation closely.”

    The department has implemented the following interventions as part of the ongoing management of the measles outbreak:

    • Outbreak response teams have been mobilised and resuscitated to address the situation effectively. The department has initiated outbreak response activities in Nala to curb the rising cases.
    • The department has improved community awareness through the distribution of information, education and communication (IEC) materials. This initiative aims to educate the public on measles prevention and encourage vaccination.
    • The department has made significant improvements in completeness of immunisation feedback (CIF) and ensured the collection of blood specimens for all laboratory samples.
    • Provincial support has been extended to the affected district throughout the outbreak. The department has collaborated with the South African Police Service (SAPS), as the local law enforcement, and community leaders to enhance outbreak awareness and response.
    • All laboratory-confirmed cases have been managed appropriately, with patients receiving the correct dose of Vitamin A and being monitored for signs and symptoms of the disease.

    SAnews.gov.za

    MIL OSI Africa

  • MIL-OSI USA: Ahead of Confirmation Hearing, Warren Presses HHS Nominee on Dangerous Anti-Vax, Anti-Abortion View

    US Senate News:

    Source: United States Senator for Massachusetts – Elizabeth Warren

    July 31, 2025

    As HHS General Counsel, Michael Stuart would serve as chief legal representative and advisor to RFK Jr., entire agency

    “I am concerned that…you will greenlight Trump Administration policies that will endanger public health, strip Americans of their abortion rights, and cause millions of Americans to lose their health insurance.”

    Text of Letter (PDF)

    Washington, D.C. – U.S. Senator Elizabeth Warren (D-Mass.) pressed Michael Stuart, nominee for General Counsel of the Department of Health and Human Services (HHS), on his dangerous anti-vaccine views, staunch anti-abortion advocacy, and more. Ahead of his confirmation hearing in front of the Senate Finance Committee later today — at which Senator Warren will question Stuart — Senator Warren sent Stuart a letter outlining her key concerns with his nomination.

    “Given your ideological views, zealous advocacy for restrictions on abortion, and record of anti-vaccine skepticism, I am concerned that, rather than faithfully following the law, you will greenlight Trump Administration policies that will endanger public health, strip Americans of their abortion rights, and cause millions of Americans to lose their health insurance,” wrote Senator Warren.

    As HHS General Counsel, Stuart would serve as the chief legal representative and advisor to Secretary Robert F. Kennedy Jr. and the entire agency. Stuart’s interpretation of the law would play a key role in ensuring HHS is actually achieving its goal of protecting Americans’ health.

    Stuart’s history of anti-vaccine views threaten to endanger Americans — especially given all that Secretary Kennedy has already done to roll back vaccine access. As a West Virginia state senator, Stuart was a key proponent of Secretary Kennedy’s “Make America Healthy Again” campaign and appears to espouse the same anti-vaccine beliefs. As HHS GC, Stuart would advise Secretary Kennedy on critical vaccine-related decisions, including legal standards related to the Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP).

    Senator Warren posed a series of questions about Stuart’s plan to advise HHS on issues related to vaccines, including whether he believes Secretary Kennedy’s decision to fire the entire ACIP panel was done lawfully and whether Secretary Kennedy has the statutory authority to unilaterally change vaccines covered by the Vaccine Injury Compensation Program program.

    Senator Warren also pressed Stuart on HHS’s massive cuts to National Institutes of Health (NIH) funding, which totaled $2.7 billion in just the first three months of this year.

    “These cuts are under continuing legal scrutiny, and if confirmed, you would be responsible for advising HHS on navigating this legal landscape so as to remain in compliance with the law,” wrote Senator Warren.

    Senator Warren highlighted Stuart’s staunch anti-abortion views, including his track record of advancing harmful misinformation about reproductive rights and supporting extremist pieces of anti-abortion legislation as a West Virginia state senator. As HHS General Counsel, Stuart would be responsible for providing legal guidance on reproductive health policies and regulations

    “President Trump has frozen millions of dollars in family planning funding, issued executive directives to undermine abortion access, amplified misinformation and sowed confusion about the safety of mifepristone, rolled back protections to shield patients and providers from violence, revoked EMTALA guidance that protected women with medical emergencies, eliminated leave and travel benefits for servicemembers, and more,” wrote Senator Warren. “It is crucial that the person serving in this position be capable of interpreting and enforcing laws and regulations concerning women’s access to reproductive health care with a neutral and health-focused lens.”

    Senator Warren also raised concerns about how Stuart will approach Secretary Kennedy’s mass firings at HHS, crack down on abusive tactics in Medicare Advantage, protect Head Start from drastic cuts, and implement Donald Trump’s “Big Beautiful Bill,” which is set to slash health care for millions of Americans.

    “HHS carries an enormous responsibility as its services and programming touch millions of American lives every day…The chief legal adviser to the Secretary of HHS must be able to, without bias,

    effectively advise the Secretary to ensure that all actions by HHS are in accordance with the law,” wrote Senator Warren. “I ask that you provide answers to my questions so that the Senate and the American people can better understand how you plan to carry out this role.”

    MIL OSI USA News

  • MIL-OSI United Kingdom: RSV vaccine prevents hospitalisation in older people and newborns

    Source: United Kingdom – Executive Government & Departments

    News story

    RSV vaccine prevents hospitalisation in older people and newborns

    RSV vaccines are 82% effective for older people and 72% for newborns when mothers are vaccinated at least 14 days before birth.

    A new UK Health Security Agency study – Effectiveness of RSV Vaccine Against RSV Associated Hospitalisation Among Adults Aged 75 to 79 years in England – in partnership with Nottingham University Hospitals and other NHS trusts, shows the RSV vaccine provided strong protection for older people, around 82% effective in preventing hospital admissions with RSV infection.

    The study also found that the vaccine is highly effective in preventing hospitalisation for older people with a chronic respiratory condition and those living with immunosuppression.

    Two new Respiratory Syncytial Virus (RSV) vaccination programmes were introduced to the NHS Vaccination Schedule in September last year; an older adults programme and a maternal programme.

    The programme for older adults offers the vaccine to those turning 75, as well as a one-off catch up campaign for all adults aged 75 to79 years.

    The maternal vaccination programme is offered to women from 28 weeks of pregnancy to protect newborns, who are at higher risk of severe illness from RSV.

    A separate new study – Vaccination in Pregnancy and RSV Hospitalisation in Infants in the UK, led by NHS paediatricians, published in the Lancet Child and Adolescent Health – found that  the maternal RSV vaccine was 72% effective in preventing hospitalisation for infants whose mothers were vaccinated more than 14 days before delivery.

    UKHSA has also today published the latest vaccine uptake figures for both RSV programmes, including the:

    • older adults programme: overall coverage as of 30 June 2025 in the catch-up cohort (adults aged 75 to 79) reached 62.9%, up from the 60.3% reported in March
    • maternal programme: of the 36,657 women reported as having given birth in March 2025, 20,051 (54.7%) had received an RSV vaccine
    • maternal coverage varied by ethnic group with the highest coverage reported among the Chinese ethnic group (73.3%) and lowest among Black and Black British Caribbean (26.4%)

    Greta Hayward, Consultant Midwife at the UK Health Security Agency, said:

    Having the RSV vaccine during every pregnancy is the best way for women to protect their newborn against RSV, as the vaccine boosts their immune system to produce more antibodies against the virus, and these then pass through the placenta to help protect their baby from the day they are born. RSV infects around 90% of children in their first 2 years of life.

    The RSV season usually starts in October and while there is no risk-free birth month, babies born in late summer or the autumn are most likely to be admitted to hospital. Hundreds of babies attend Emergency Departments each day for bronchiolitis through most of November and December. That is why it is so important that over the summer pregnant women reaching 28 weeks of pregnancy, ensure they are vaccinated as soon as possible.

    Dr Conall Watson, Immunisation Consultant at the UK Health Security Agency, said:

    The evidence clearly shows the RSV vaccine for pregnant women is highly effective and will give much reassurance to parents, knowing their newborn is protected from birth, when they are at much greater risk from RSV.

    As a parent and health professional I can’t stress enough the importance of getting the RSV vaccine during every pregnancy. We recommend vaccination in week 28 or soon after but if you are later on in your pregnancy and still haven’t had your vaccine please contact your maternity service or GP practice to arrange one.

    RSV can be a particularly serious infection for older people, so this new evidence will also give much reassurance that having the RSV jab will greatly reduce their chances of ending up in hospital.

    While the uptake of the RSV vaccine continues to rise, we want to see every single pregnant woman and eligible older person getting protected. The virus picks up in the autumn, so don’t put if off over the summer – as soon as you reach your 75th birthday or week 28 of pregnancy get the vaccine for healthy peace of mind.

    UKHSA has published its first RSV Annual Report, which looks back at the 2024 to 2025 RSV season, providing analysis on disease pattern, vaccine uptake and vaccine impact.

    The surveillance shows RSV activity started across all UK nations around week 42 of 2024 (week starting 14 October) and peaked around weeks 47 to 49 2024 (18 November to 8 December), before steadily declining and reaching baseline activity around weeks 7 to 8 2025 (10 to 23 February).

    The Report also details UKHSA’s analysis from the primary care surveillance, which involves swabbing in around 300 GP Practices in England when a patient presents with an acute respiratory infection (ARI). This found that by age group, the highest RSV positivity (% of laboratory confirmed RSV cases out of total ARI swabs) was observed in children under 5 years; with positivity peaking at 53.1% in week 46 (11-17 November).

    Among those aged 75 years and above, the highest RSV positivity rate was 18.5% reported in week 49 (2 to 8 December).

    Surveillance of patients attending hospital emergency departments (ED) in England found that among infants (babies under 1), bronchiolitis peaked in late November. This is the main clinical presentation of infant RSV and RSV is the primary pathogen causing bronchiolitis.

    Updates to this page

    Published 31 July 2025

    MIL OSI United Kingdom

  • MIL-OSI United Kingdom: RSV vaccine highly effective in preventing hospitalisation

    Source: United Kingdom – Government Statements

    News story

    RSV vaccine highly effective in preventing hospitalisation

    RSV vaccines are 82% effective for older people and 72% for newborns when mothers are vaccinated at least 14 days before birth.

    A new UK Health Security Agency study – Effectiveness of RSV Vaccine Against RSV Associated Hospitalisation Among Adults Aged 75 to 79 years in England – in partnership with Nottingham University Hospitals and other NHS trusts, shows the RSV vaccine provided strong protection for older people, around 82% effective in preventing hospital admissions with RSV infection.

    The study also found that the vaccine is highly effective in preventing hospitalisation for older people with a chronic respiratory condition and those living with immunosuppression.

    Two new Respiratory Syncytial Virus (RSV) vaccination programmes were introduced to the NHS Vaccination Schedule in September last year; an older adults programme and a maternal programme.

    The programme for older adults offers the vaccine to those turning 75, as well as a one-off catch up campaign for all adults aged 75 to79 years.

    The maternal vaccination programme is offered to women from 28 weeks of pregnancy to protect newborns, who are at higher risk of severe illness from RSV.

    A separate new study – Vaccination in Pregnancy and RSV Hospitalisation in Infants in the UK, led by NHS paediatricians, published in the Lancet Child and Adolescent Health – found that  the maternal RSV vaccine was 72% effective in preventing hospitalisation for infants whose mothers were vaccinated more than 14 days before delivery.

    UKHSA has also today published the latest vaccine uptake figures for both RSV programmes, including the:

    • older adults programme: overall coverage as of 30 June 2025 in the catch-up cohort (adults aged 75 to 79) reached 62.9%, up from the 60.3% reported in March
    • maternal programme: of the 36,657 women reported as having given birth in March 2025, 20,051 (54.7%) had received an RSV vaccine
    • maternal coverage varied by ethnic group with the highest coverage reported among the Chinese ethnic group (73.3%) and lowest among Black and Black British Caribbean (26.4%)

    Greta Hayward, Consultant Midwife at the UK Health Security Agency, said:

    Having the RSV vaccine during every pregnancy is the best way for women to protect their newborn against RSV, as the vaccine boosts their immune system to produce more antibodies against the virus, and these then pass through the placenta to help protect their baby from the day they are born. RSV infects around 90% of children in their first 2 years of life.

    The RSV season usually starts in October and while there is no risk-free birth month, babies born in late summer or the autumn are most likely to be admitted to hospital. Hundreds of babies attend Emergency Departments each day for bronchiolitis through most of November and December. That is why it is so important that over the summer pregnant women reaching 28 weeks of pregnancy, ensure they are vaccinated as soon as possible.

    Dr Conall Watson, Immunisation Consultant at the UK Health Security Agency, said:

    The evidence clearly shows the RSV vaccine for pregnant women is highly effective and will give much reassurance to parents, knowing their newborn is protected from birth, when they are at much greater risk from RSV.

    As a parent and health professional I can’t stress enough the importance of getting the RSV vaccine during every pregnancy. We recommend vaccination in week 28 or soon after but if you are later on in your pregnancy and still haven’t had your vaccine please contact your maternity service or GP practice to arrange one.

    RSV can be a particularly serious infection for older people, so this new evidence will also give much reassurance that having the RSV jab will greatly reduce their chances of ending up in hospital.

    While the uptake of the RSV vaccine continues to rise, we want to see every single pregnant woman and eligible older person getting protected. The virus picks up in the autumn, so don’t put if off over the summer – as soon as you reach your 75th birthday or week 28 of pregnancy get the vaccine for healthy peace of mind.

    UKHSA has published its first RSV Annual Report, which looks back at the 2024 to 2025 RSV season, providing analysis on disease pattern, vaccine uptake and vaccine impact.

    The surveillance shows RSV activity started across all UK nations around week 42 of 2024 (week starting 14 October) and peaked around weeks 47 to 49 2024 (18 November to 8 December), before steadily declining and reaching baseline activity around weeks 7 to 8 2025 (10 to 23 February).

    The Report also details UKHSA’s analysis from the primary care surveillance, which involves swabbing in around 300 GP Practices in England when a patient presents with an acute respiratory infection (ARI). This found that by age group, the highest RSV positivity (% of laboratory confirmed RSV cases out of total ARI swabs) was observed in children under 5 years; with positivity peaking at 53.1% in week 46 (11-17 November).

    Among those aged 75 years and above, the highest RSV positivity rate was 18.5% reported in week 49 (2 to 8 December).

    Surveillance of patients attending hospital emergency departments (ED) in England found that among infants (babies under 1), bronchiolitis peaked in late November. This is the main clinical presentation of infant RSV and RSV is the primary pathogen causing bronchiolitis.

    MIL OSI United Kingdom

  • MIL-OSI United Kingdom: Latest data shows measles cases remain high

    Source: United Kingdom – Executive Government & Departments

    News story

    Latest data shows measles cases remain high

    Measles activity has increased since April 2025 and the UKHSA is continuing to oversee the public health risk assessment.

    The UK Health Security Agency (UKHSA) is today urging parents to prioritise vaccine catch-up appointments during the summer break, with latest data showing continued high levels of measles cases amid fears of a further surge once the new school term begins.

    Measles activity has increased since April 2025 and the UKHSA is continuing to oversee the public health risk assessment and working with local partners on the response.

    The latest monthly update on measles cases in England published today shows that an additional 145 measles cases have been reported since the last publication on July 3. Cases continue to predominantly be in children under the age of 10 years with London and parts of the North West driving the increase most.

    The latest measles epidemiology report on the UKHSA Data Dashboard today reports:

    • since 1 January, there have been 674 laboratory confirmed measles cases reported in England, an increase of 145 cases since the last report on 3 July 2025

    • 48% (322/674) of these cases have been in London, 16% (111 out of 674) in the North West, and 10% (65/674) in the East of England

    There has also been a global increase in measles cases, including Europe, over the last year. UKHSA is concerned that holiday travel and international visits to see family this summer could lead to rising measles cases in England when the new school term begins.

    Dr Vanessa Saliba, UKHSA Consultant Epidemiologist, said:

    The summer months offer parents an important opportunity to ensure their children’s vaccinations are up to date, giving them the best possible protection when the new school term begins. It is never too late to catch up. Do not put it off and regret it later.

    Measles spreads very easily and can be a nasty disease, leading to complications like ear and chest infections and inflammation of the brain with some children tragically ending up in hospital and suffering life-long consequences.

    Two doses of the MMR vaccine is the best way to protect yourself and your family from measles. Babies under the age of 1 and some people who have weakened immune systems cannot have the vaccine and are at risk of more serious complications if they get measles. They rely on the rest of us getting the vaccine to protect them.

    Dr Amanda Doyle, National Director for Primary Care and Community Services at NHS England, said:

    Vaccination is the best protection against measles, which is highly contagious and can cause serious health problems. The MMR vaccine is provided free by the NHS and I would urge all parents to check their child’s vaccination records before the new school year or summer travel, particularly as Europe is reporting the highest number of measles cases in 25 years.

    While the NHS delivered tens of thousands of additional MMR vaccinations last year, too many eligible children remain unvaccinated, and we are working with local authorities and the UK Health Security Agency to reach more youngsters, with enhanced vaccination offers in areas with higher cases, including vaccination buses and community catch-up sessions.

    The first MMR vaccine is offered to infants when they turn one year old and the second dose to pre-school children when they are around 3 years and 4 months old. 

    Around 99% of those who have 2 doses will be protected against measles and rubella. Although mumps protection is slightly lower, cases in vaccinated people are much less severe. 

    Anyone, whatever age, who has not had 2 doses can contact their GP surgery to book an appointment.

    Read more information on measles, mumps and rubella.

    Updates to this page

    Published 31 July 2025

    MIL OSI United Kingdom

  • MIL-OSI United Kingdom: expert reaction to latest UKHSA data showing measles cases remain high

    Source: United Kingdom – Executive Government & Departments

    Scientists comment on latest data from the UK Health Security Agency (UKHSA) that shows measles cases remain high. 

    Dr Ben Kasstan-Dabush, Assistant Professor of Global Health & Development at the London School of Hygiene & Tropical Medicine (LSHTM), said:

    “It is no surprise that Hackney has seen the highest number of measles cases over the past four weeks. To prevent measles outbreaks, the WHO recommends that 95% of people are fully vaccinated with two doses of the MMR vaccine. In 2023-2024, MMR coverage in Hackney was lowest by local authority in England and just 60.8% had received both MMR doses by the age of five, compared with 83.9% of children on average across England. Without this vital vaccine coverage, children have been left as sitting ducks for a measles outbreak.

    “Hackney’s population is unique and a ‘one-size fits all’ approach will not solve the problem. The borough’s population is diverse and younger, with almost one in three residents aged under 24. Hackney also has among the highest numbers of children living in low income families in London and around one in four children are Haredi (strictly Orthodox Jewish). In this context, every family will have their own challenges and pressures, so how can we expect under-funded, inflexible delivery strategies to offer equitable access?

    “Local clinics and teams are working incredibly hard to protect children and prevent another child death from measles in the UK. But it is extremely difficult to sustain positive results when funding to commission vaccination projects and new professionals roles are short-term and unpredictable.

    “Together with a local GP in Hackney, Dr Tehseen Khan, we have been researching ways to ensure vital vaccines are accessible to those who need them. This includes evaluating how primary care teams in the area offer parents more convenient appointments through Sunday walk-in clinics and allowing parents to bring several children to one appointment. However, primary care cannot solve these challenges alone. I would encourage any parent with questions or concerns, or anyone who’s unsure on their own vaccination status, to reach out to their local GP surgery, as it’s never too late to catch up on the MMR vaccine.

    “Political decisions are threatening the ability to make long-term improvements in vaccination coverage in Hackney and nationwide. Integrated Care Boards, the NHS organisations that plan and commission health services for their local populations, are expected to reduce operational costs by 50%. This will be disastrous for vaccine coverage recovery efforts, and raises fundamental questions about how the government’s 10 year ‘Fit for the Future’ plan can realistically be implemented.”

    https://ukhsa-newsroom.prgloo.com/news/latest-data-show-measles-cases-remain-high-with-london-and-parts-of-the-north-west-driving-increase

    Declared interests

    Dr Ben Kasstan-Dabush: Dr Ben Kasstan- Dabush is Assistant Professor of Global Health & Development at the London School of Hygiene & Tropical Medicine. He is currently working on vaccine delivery research in Hackney, funded by the British Medical Association Foundation for Medical Research (2023 Kathleen Harper Award, in collaboration with Dr Tehseen Khan). This builds on previous work funded by the NIHR Health Protection Research Unit in Vaccines & Immunisation, a collaboration between LSHTM and UKHSA. Ben provides regular consultation to UKHSA.”

    MIL OSI United Kingdom

  • MIL-OSI New Zealand: Pharmac expands access to meningococcal B vaccine for children under 5

    Source: PHARMAC

    Pharmac is extending access to the meningococcal B vaccine (Bexsero), with up to 77,000 more children able to benefit.

    From 1 September 2025, all children under five years of age will be eligible for funded doses of Bexsero, regardless of whether they started or completed their vaccine course in their first year. This replaces the current catch-up programme, which ends on 31 August 2025.

    The vaccine is already part of the childhood immunisation schedule for children up to 12 months of age. The new eligibility criteria mean that children who missed earlier doses can still be protected.

    “We know how serious meningococcal disease can be, especially for young children,” says Pharmac’s Manager Pharmaceuticals Adrienne Martin. “By expanding access, we’re helping families complete their child’s vaccine course and improving protection for those most at risk.”

    Children under five are the most vulnerable to serious illness from meningococcal disease. This change supports better protection for this high-risk group and makes it easier for families to access the vaccine.

    “This decision is about removing barriers,” says Martin. “We want to ensure that no child misses out on protection just because they couldn’t complete their vaccine course in their first year.”

    Health New Zealand’s National Public Health Director Dr Nick Chamberlain says it welcomes Pharmac’s decision to extend access to the meningococcal B vaccine.

    “Pharmac’s move to extend access to Bexsero for all children under five is a significant step forward in protecting those most vulnerable to meningococcal disease. 

    “This change brings clarity for the health sector and removes barriers for families, making it easier to complete the vaccine course. Health New Zealand will continue working closely with providers to support the rollout and ensure eligible children receive this important protection,” said Dr Chamberlain.

    While the eligibility criteria for older children and adults at higher risk remain unchanged, Pharmac has clarified the wording to make it easier to understand. Teenagers and young adults living in shared accommodation, such as boarding schools, halls of residence, military barracks, and prisons, continue to be eligible under the current rules.

    MIL OSI New Zealand News

  • MIL-OSI Asia-Pac: DoIT MOEA AI-Enhanced Vaccines and Anti-Pulmonary Inflammatory Drugs Shine at BIO Asia-Taiwan 2025: Health Maintenance, Prevention, and Treatment-A Triple Strategy for a Resilient and Healthy Taiwan

    Source: Republic of China Taiwan

    The Department of Industrial Technology (DoIT) of the Ministry of Economic Affairs (MOEA) convened three research foundations-ITRI (Industrial Technology Research Institute), FIRDI (Food Industry Research and Development Institute), and the Development Center for Biotechnology (DCB)-to establish the DoIT pavilion, which held its opening ceremony at BIO Asia-Taiwan 2025. The pavilion showcases 12 innovative technological achievements in health maintenance, disease prevention, and treatment, highlighting Taiwan’s capabilities in biomedical research and development while injecting new momentum into the health industry. Key exhibit technologies include the “Smart Processing & Equipment Integration for Plant-Based Drinks,” designed for the elderly; the “Long-Lasting Immunity of CD40 Ligand Ribonucleic Acid Vaccine Adjuvant,” developed to extend vaccine effectiveness; and the “Novel Selective FPR1 Antagonist,” which reduces side effects while improving therapeutic outcomes.

    Senior Technical Specialist of the Department of Industrial Technology (DoIT), Mr. Tai Chien-Cheng , indicated that in the face of global political and economic uncertainties, pharmaceuticals have become essential strategic commodities vital to public well-being and safety. Taiwan’s strengths in research and development (R&D), regulatory frameworks, and manufacturing processes position it as a reliable partner for international pharmaceutical companies. To enhance global integration and expand cooperation, Taiwan should improve collaboration across both upstream and downstream industries, thereby increasing technical density and strengthening global competitiveness. He advocated for DoIT to continue connecting foundational resources and implementing supportive policies for R&D funding and tools to facilitate industrial advancement. The pavilion symbolizes the long-term commitment of research institutions to the “Three-Stage, Five-Level Prevention” framework, linking applications from “precision medicine” to “palliative care,” and showcasing the government’s proactive efforts in realizing the “Healthy Taiwan” policy.

    In addition, several breakthroughs driven by or related to artificial intelligence (AI) are highlighted among the 12 innovative technologies showcased in the pavilion.

    ITRI presents “Tumor-Derived Exosomes Enrichment and Detection Platform”, and “One-Stop Exosome Isolation and Characterization Services”. FIRDI showcases “Intelligent Preparation of Nutritional Beverages” in AI-powered biomedicine research and development.

    ITRI’s “In Vivo Delivery of mRNA Encoding CAR to Macrophages for Solid Tumor Therapy” and “An Eye Drop Product for Dry AMD Treatment”. DCB showcases “Rejuvenating CAR-T Cells Through the Secretion of Antibodies Targeting Immunosuppressive Axis” and “NTSR1-ADC: A Novel Therapeutics for Head and Neck Cancer” for cancer and ophthalmic conditions. These technologies highlight the progress in therapeutic drug development and the emergence of new treatment breakthroughs.

    Additionally, FIRDI contributes its technical expertise through the development of “Plant-based animal fat alternative technology” and “Microorganisms in the Modification of Food Texture and Flavor”. These innovations aim to redefine the texture and quality of plant-based meats, infusing the plant-based industry with dynamic advancements.

    Spokesperson: Ministry of Economic Affairs Department of Industrial Technology (Taiwan) Deputy Director General Chou Chung-Pin
    Telephone:02-23212200 extension 8121
    Email:cbjou@moea.gov.tw

    Contact person:Ministry of Economic Affairs Department of Industrial Technology (Taiwan) Technical Specialist Tai Chien-Cheng
    Telephone:02-23212200 extension 8180
    Email:cctai@moea.gov.tw

    Media contact:Ministry of Economic Affairs Department of Industrial Technology (Taiwan) Researcher
    Telephone:02-23212200 extension 8155,0910-660322
    Email:yschi@moea.gov.tw

    MIL OSI Asia Pacific News

  • Vaccines prevented over 2.5 million COVID deaths worldwide: Study

    Source: Government of India

    Source: Government of India (4)

    Vaccines have prevented more than 2.5 million deaths caused by SARS-CoV-2, the virus behind COVID-19, according to a new study.

    Led by researchers from the Catholic University of the Sacred Heart in Italy, the study found that one COVID-related death was avoided for every 5,400 vaccine doses administered.

    About 82% of the lives saved involved people who were vaccinated before contracting the virus. Additionally, 57% of the total lives saved were during the Omicron period, and 90% of the deaths prevented were among individuals aged 60 and above.

    Overall, the study estimated that vaccines saved 14.8 million years of life globally—equivalent to one year of life saved for every 900 doses administered. The findings were published in the JAMA Health Forum journal.

    “Previous studies attempted to estimate lives saved by vaccines using different models, timeframes, or regional data,” said Dr. Angelo Maria Pezzullo and Dr. Antonio Cristiano. “However, this study is the most comprehensive to date. It uses global data, includes the Omicron period, quantifies life years saved, and is based on fewer assumptions regarding pandemic trends.”

    For the analysis, researchers examined global population data and applied a series of statistical models to determine who became ill with COVID-19—either before or after vaccination—and during or after the Omicron period, including age and mortality outcomes.

    “We compared this data with modeled estimates assuming no COVID vaccination. This allowed us to calculate how many people were saved and the number of life years gained due to vaccination,” explained Dr. Pezzullo.

    The study also revealed that 76% of the saved life years were among people over 60. However, residents of long-term care facilities accounted for only 2% of the total benefit.

    Children and adolescents accounted for just 0.01% of lives saved and 0.1% of life years saved. Similarly, young adults aged 20–29 contributed 0.07% of lives saved and 0.3% of life years saved, the researchers noted.

    —IANS

  • MIL-OSI United Nations: Country heat policy review: Republic of Korea

    Source: UNISDR Disaster Risk Reduction

    The Republic of Korea has developed a comprehensive and multi-tiered approach to managing extreme heat, integrating national policies, institutional frameworks, local government initiatives, and community-based actions.

    National frameworks such as the Climate Change Adaptation Plan and the Basic Plan for the Promotion of Climate Change Response guide efforts to address extreme heat as part of broader climate resilience strategies.

    The Korea Meteorological Administration (KMA) plays a key role by issuing heatwave warnings and impact-based heatwave forecasts , using an updated alert system based on Daily Maximum Perceived Temperature, which takes humidity into account to better reflect health impacts.

    Additionally, the Korean Disease Control and Prevention Agency (KDCA), alongside the KMA, published the first Climate Health Impact Assessment Report in March 2022. In this report, published every five years, heat-related deaths and illnesses are identified as key health indicators to be monitored.

    Collaboration among key institutions enables a coordinated response to heat risks across sectors-including health, industry, livestock, agriculture, and aquaculture-each managed by distinct governmental bodies, and consolidated guidelines have been given. Healthcare preparedness has been strengthened with the publication of the Climate Health Impact Assessment Report, which monitors heat-related illnesses and deaths. Hospitals and healthcare centres, particularly those with emergency services, have improved their capacity to manage heat-related conditions. Additionally, the Ministry of the Interior and Safety, Republic of Korea, has called for meetings with other governmental institutions across different sectors.

    Local governments, especially in urban areas like Seoul, lead heat mitigation efforts through urban cooling strategies, public awareness campaigns, and the expansion of green spaces.

    Initiatives include installing green roofs, promoting public transportation through the Climate Card programme, and constructing cooling stations in public areas to offer relief from heat.

    Public-private partnerships have been instrumental in enhancing the country’s resilience to extreme heat. The Seoul Metropolitan Government collaborates with private real estate developers to implement green rooftops across the city, while telecommunications company SK Telecom partners with KMA to send real-time heatwave alerts to millions of subscribers.

    Currently, emergency information about heatwaves is being provided through the cell broadcast service in Korea. Hyundai Motor Company collaborates with local governments in urban cooling projects, such as installing cooling stations in public areas. These stations provide cool air and water, offering relief to residents and visitors during heatwaves. LG Electronics partners with Seoul National University Hospital to develop and distribute advanced cooling technologies for healthcare facilities, ensuring hospitals are equipped with energy-efficient air conditioning systems that improve patient care during extreme heat periods. These examples demonstrate the impact of leveraging resources and expertise to enhance resilience to extreme heat.

    On the international stage, the Republic of Korea partners with organizations such as the World Health Organization (WHO) Asia-Pacific Centre for Environment and Health, the Green Climate Fund, and the International Vaccine Institute-all located in the country-to advance knowledge and technical capacity for climate resilience. These collaborations contribute to their leadership in responding to extreme heat.

    Through its coordinated approach involving national agencies, local governments, public-private partnerships, and international collaboration, the Republic of Korea has strengthened its ability to manage extreme heat. Key achievements include the updated heatwave alert system, localized urban cooling projects, and strengthened healthcare preparedness, positioning the country as a regional leader in climate adaptation.

    MIL OSI United Nations News

  • MIL-OSI Africa: Committee on Agriculture Commends Improved Performance of Agricultural Research Council (ARC), National Agricultural Marketing Council (NAMC) and Perishable Products Export Control Board (PPECB) in the Fourth Quarter of 2024/25

    Source: APO


    .

    The Portfolio Committee on Agriculture welcomed the briefings it received yesterday from the Agricultural Research Council (ARC), National Agricultural Marketing Council (NAMC), and the Perishable Products Export Control Board (PPECB) on their performance in the fourth quarter of the 2024/25 financial year and commended their notable performance.

    In welcoming the briefings from the three entities of the Department of Agriculture, the Chairperson of the Committee, Ms Dina Pule, said the committee was happy about the progress that the entities reported to the committee. She said the committee notes the hard work the entities have demonstrated and called for more improvement in all the areas of work that included implementation of the Auditor General’s recommendations on their last audit outcomes.

    The ARC reported that funding for building of the new Foot-and-mouth Disease (FMD) Vaccine Facility is still a challenge and that, efforts to obtain the required funding for the new facility remains a priority. The entity reported that field assessment of the FMD vaccine in Mpumalanga and Limpopo is ongoing and the study on vaccine safety in pregnant cows and young calves has been initiated.

    In appreciating the performance of the NAMC, the committee called on the entity to do more on finding market access for the small-scale farmers as markets are alfa and omega for their growth, survival and meaningful contribution to the South African economy and for national food security.

    The Chairperson told the Deputy Minister of the Department of Agriculture, Ms Zoleka Capa, who led the departmental delegation, that the committee notes with appreciation the accountability of both the Minister and his Deputy that they demonstrate to the committee.

    The Chairperson also said that accountability is a critical starting point for the success of the department. “We deeply appreciate your availability to our meetings with the department. Your presence solidifies the accountability of the department to the committee and the oversight responsibility of the committee over the department,” emphasised the Chairperson.

    Distributed by APO Group on behalf of Republic of South Africa: The Parliament.

    MIL OSI Africa

  • MIL-OSI United Kingdom: Staying healthy on holiday – what you need to know

    Source: City of Wolverhampton

    Travel can expose people to unfamiliar environments, climates and health risks, so simple preparations can make a significant difference.

    The council is advising travellers to ensure they and their families are in good health before departure, to pack necessary medications and first aid supplies, and to check the latest travel guidance for the area they are visiting, including local risks, weather conditions, and any recommended precautions. For individuals living with long term health conditions, this includes making sure symptoms are stable and well managed ahead of their trip.

    Vaccination checks are also vital, including routine vaccinations such as MMR (measles, mumps, and rubella), which remains critical given the rise of measles cases globally. Travellers heading to destinations such as Pakistan, India or parts of Africa, Asia and South America may require travel specific vaccines or medication and so are advised to speak to their GP, pharmacist or travel clinic as soon as possible.

    While on holiday, maintaining hygiene is crucial, including regular hand washing or the use of hand sanitiser when water is unavailable, and drinking bottled water in countries with unsafe tap water. Travellers should remain vigilant for common ailments such as upset stomachs and mosquito borne illnesses, and take care around unfamiliar animals due to the risk of rabies.

    Anyone experiencing symptoms such as high fever, prolonged diarrhoea, severe pain, unusual rashes or yellowing of the skin should seek medical advice. People who are bitten or scratched by an animal in a rabies risk country, or are returning from a malaria risk region with signs of illness, should get help urgently.

    Councillor Obaida Ahmed, Cabinet Member for Health, Wellbeing and Community, said: “Taking a few proactive steps before and during your travels can protect your health and give you peace of mind to enjoy your holiday to the fullest. From making sure you’re up to date with vaccinations to knowing what to do if you feel unwell while you’re away, it’s about being prepared, wherever you’re heading this summer.”

    For further information, please visit TravelHealthPro.

    MIL OSI United Kingdom

  • MIL-OSI Africa: Motsoaledi calls for innovative vaccine solutions to combat TB

    Source: Government of South Africa

    Minister of Health, Dr Aaron Motsoaledi, has stressed the urgent need for innovative solutions to combat tuberculosis (TB), a disease that has historically affected not just South Africa but also countries around the world.

    “We are here because we believe that TB – a disease that has shaped the history and health of our country and indeed, the whole world – can be ended. Not through words alone, but through action, partnership, and innovation,“ he said on Thursday. 

    The Minister was delivering a keynote address at the country’s TB Vaccine Preparedness Workshop held in Johannesburg. The workshop is aimed at advancing policy and decision-making for the introduction of TB vaccines.

    Addressing policymakers, scientists and community leaders, Motsoaledi stated that the upcoming phase will introduce preventative TB vaccination measures, which will also enhance the ongoing fight against HIV and Aids.

    For over a century, South Africa has relied on the Bacille Calmette-Guérin (BCG) vaccine to protect its children from TB, but the Minister pointed out that there has been no tool that can protect adolescents and adults. 

    “These are the very groups most at risk of getting sick and transmitting TB.” 

    With several new TB vaccine candidates in the late stages of clinical trials, the most promising options are expected to be available in the next few years. 

    This workshop positioned the country as one of the first that is ready to deliver a new generation of TB vaccines to the most vulnerable populations, including adolescents and adults.

    The Minister expressed confidence that the upcoming clinical trials would yield positive results, potentially leading to a new vaccine for older age groups within the next few years.

    TB is a leading cause of death from an infectious disease and a major contributor to ill-health in South Africa and globally.

    “Imagine the day when we announce the availability of the vaccine for tuberculosis,” he said, likening it to “the day of true freedom from slavery” for those suffering from the disease. 

    Motsoaledi described the disease as a form of “devastating slavery” that exacerbates poverty and leads to premature death.

    “South Africa is not waiting for the world to act. We are preparing – intentionally, early and inclusively.” 

    The Minister has used the first national gathering dedicated to the TB vaccine readiness platform to reiterate South Africa’s commitment to lead by example in the global fight against TB and HIV. 

    “When South Africa wins against TB and HIV and Aids the world will win the war,” he said. 

    He told the attendees that through his tenure as Health Minister, he consistently sought to elevate the profile of TB on a global scale. 

    Motsoaledi recalled his 2018 address at the United Nations, where he rallied for world leaders to commit to addressing the TB crisis. 

    “While global attention has often turned to emerging health threats, South Africa has remained focused on the enduring challenge of TB,” he said. 

    He also acknowledged the disease’s severe impact on communities already struggling with HIV.

    “Today’s discussions remind us that vaccine introduction is not just about science – it is about health systems. It is about trust. It is about readiness.”

    He also used the platform to emphasise the importance of preparing the health sector for the rollout of the TB vaccine.

    The agenda for the workshop highlighted key thematic areas crucial for readiness, including generating evidence for policy and investment, strengthening delivery systems for TB vaccines, and ensuring manufacturing and supply chain readiness.

    “Investment in human life means everything,” he said, stressing the need for robust financial backing to ensure effective vaccine deployment.

    The Minister took the time to urge stakeholders to foster community trust and strong advocacy to ensure widespread acceptance of the TB vaccine upon its introduction.

    “We must walk the path with our people,” he said. – SAnews.gov.za

    MIL OSI Africa

  • MIL-OSI Asia-Pac: DH investigates incident of RCHE and RCHD administering COVID-19 vaccines beyond recommended use-by date

    Source: Hong Kong Government special administrative region

    DH investigates incident of RCHE and RCHD administering COVID-19 vaccines beyond recommended use-by date 
    Upon reviewing the vaccine orders and vaccination records, the DH found that the doctor concerned visited Oi Tak Old People’s Home Limited, an RCHE in Yuen Long, on June 14, July 7 and July 9 to provide vaccination services. During these visits, he administered Spikevax JN.1 COVID-19 vaccines that were beyond the recommended use-by date to 18 residents. According to the manufacturer’s recommendation, the vaccine should be stored at 2 to 8 degrees Celsius after thawing and should be used within 30 days.
     
    Upon further investigation, the DH found that the doctor concerned had also provided vaccination services at an RCHD, named Quality Rehabilitation Home, in Kwai Tsing District on March 26. During the visit, he administered Spikevax JN.1 COVID-19 vaccines that were beyond the recommended use-by date to a resident and two staff members.
     
    The DH is highly concerned about the incident and has taken immediate actions to follow up on the health conditions of the affected persons. It has been confirmed that none of the affected residents or staff at the RCHE or the RCHD suffered from adverse events as a result of the vaccination. The DH has sought information from the vaccine manufacturer on the safety and efficacy of the vaccine under the above circumstances. Taking into account the history of COVID-19 vaccination and infection of the affected persons, the DH advised that there is no need for the affected individuals to be revaccinated. The DH has instructed the doctor in question to monitor the health conditions of the affected residents. At the request of the DH, the visiting doctor will explain the incident to the affected persons or their relatives and discuss subsequent arrangements.
     
    Meanwhile, the DH has inspected the RCHE and the RCHD concerned to check the storage of vaccines and vaccination procedures. To avoid the recurrence of similar incidents, the staff have been urged to follow the requirements of regular checking of the recommended use-by date of the vaccines, separate storage of vaccines with different recommended use-by dates, and timely disposal of expired vaccines in accordance with the guidelines of the COVID-19 Vaccination Programme.
     
    The DH has suspended the vaccination service of the doctor concerned under the Vaccination Schemes and will continue to follow up on whether the two institutions concerned have complied with the relevant guidelines of the DH. If any person is found to have breached the guidelines or the terms and conditions of the COVID-19 Vaccination Programme, the DH will handle the case according to established procedures.
    Issued at HKT 18:07

    NNNN

    MIL OSI Asia Pacific News

  • MIL-OSI Africa: SA hosts key TB vaccine workshop

    Source: Government of South Africa

    South Africa is making a significant move in its global response to Tuberculosis (TB) by hosting a pivotal TB Vaccine Preparedness Workshop. 

    This event is part of ongoing efforts to decrease the incidence and mortality of TB, under the ‘End TB Strategy,’ a global initiative established by the World Health Organisation (WHO) aimed at ending the TB epidemic by 2035.

    TB is a leading cause of death as an infectious disease and a major contributor to ill-health in South Africa and globally. 

    The Health Department said vaccination has proven to be one of the main effective and feasible ways to contain the spread of infectious diseases.

    “With several new TB vaccine candidates in the late stages of clinical trials, and the most promising expected to be available in the next few years, this workshop will position the country as one of the first to deliver a new generation of TB vaccines to the most vulnerable populations, including adolescents and adults.”

    According to the department, the Bacille Calmette-Guérin (BCG) vaccine remains the only licensed TB vaccine available, and it has been used to effectively prevent severe TB in infants and young children for over 100 years.

    The two-day meeting, starting today, 23 July 2025, brings together scientists, policymakers, academic experts, donor funders, health regulators, TB survivor advocates, and civil society leaders. 

    This gathering signals a new era of proactive planning and coordinated efforts across multiple sectors to expedite access to life-saving innovations that could significantly reduce TB deaths and infections.

    South Africa has one of the world’s highest TB burdens and has played a leading role in global TB vaccine development. 

    The workshop is being convened by the Department of Health and WHO, in collaboration with various stakeholders in the health sector. 

    The department said delegates will work toward developing a country-specific roadmap for TB vaccine introduction, including how to strengthen readiness across supply chains, financing, community engagement, health worker training, and policy frameworks.

    “This is the first national meeting of its kind focused exclusively on TB vaccine rollout preparedness. 

    “It signals South Africa’s intent to lead from the front in accelerating access to new health technologies,” the Health Department said. 

    Minister of Health, Dr Aaron Motsoaledi, will deliver the keynote address at the workshop on Thursday, 24 July. 

    He will be joined by the WHO Representative to South Africa, Shenaaz El-Halabi, and other senior health officials. – SAnews.gov.za

    MIL OSI Africa

  • MIL-OSI Analysis: How falling vaccination rates are fuelling the antibiotic resistance crisis

    Source: The Conversation – Canada – By Ruchika Gupta, Assistant Professor and Medical Microbiologist, Department of Pathobiology and Lab Medicine, London Health Sciences Centre and Schulich School of Medicine and Dentistry, Western University

    Antibiotic resistance is one of the biggest health threats we face today. It’s often blamed on the overuse of antibiotics, and for a good reason. But there’s another major factor quietly driving this crisis that doesn’t get as much attention: low vaccination rates.

    In early 2025, Ontario had a measles outbreak with 2,200 cases as of mid-July, mostly in people who hadn’t been fully vaccinated. An outbreak in Alberta that began in March has expanded to more than 1,300 cases as of mid-July.

    Measles had been eliminated in Canada since 1998, but it’s now reappearing, largely due to missed or delayed vaccinations. On the surface, these might seem like a limited viral outbreak. But the ripple effects go much further, causing more illness, more complications and, ultimately, more antibiotic use.

    Why measles can lead to antibiotic use

    Measles itself is a viral infection, so antibiotics don’t treat it directly. But the virus weakens the immune system, leaving people vulnerable to bacterial infections like pneumonia or ear infections, conditions that do require antibiotics.

    Unsurprisingly, this pattern isn’t new. A 2019 study published in Pediatrics showed that many children hospitalized with measles in the United States developed secondary infections that required antibiotic treatment, especially pneumonia and ear infections.

    While data from the Ontario outbreak is still being analyzed, experts expect a similar surge in antibiotic prescriptions to treat these preventable complications.

    The antibiotic resistance chain reaction

    Every time we use antibiotics, we give bacteria a chance to adapt.
    (NIAID), CC BY

    Here’s where it gets dangerous. Every time we use antibiotics, we give bacteria a chance to adapt. The most vulnerable bacteria die, but tougher ones survive and spread. This leads to antibiotic resistance where treatments that used to work no longer do.

    Even appropriate use of antibiotics, like treating a bacterial infection after measles, adds to the problem. And the more often we need to prescribe antibiotics, the faster this resistance builds.

    A 2022 global study published in The Lancet estimated that antimicrobial resistance directly caused 1.27 million deaths in 2019 and contributed to many millions more. As resistance spreads, doctors are forced to use more toxic, expensive or last-resort drugs, and sometimes, no effective treatment exists at all.

    Antibiotic resistance means that treatments that used to work no longer do.
    (NIAID), CC BY

    How vaccines help fight resistance

    Vaccines are one of the most powerful tools we have not just to prevent disease, but to reduce antibiotic use and slow resistance. By stopping infections before they happen, vaccines reduce the need for antibiotics in the first place.

    Some vaccines protect directly against bacteria. Pneumococcal vaccines (PCV13, PCV15, PCV20) guard against a major cause of pneumonia, brain infections and ear infections. Haemophilus influenzae type b (Hib) and diphtheria vaccines prevent other respiratory bacterial diseases.

    Other vaccines protect against viruses, which can weaken the body and open the door to bacterial infections called as secondary bacterial infections.

    The MMR (measles-mumps-rubella) vaccine not only prevents measles but also reduces the chance of bacterial pneumonias that often occur after measles due to immunosuppression.

    The seasonal flu and COVID-19 vaccines help prevent viral infections that can trigger secondary bacterial complications.

    The rotavirus vaccine that protects against diarrheal disease in children has also been shown to reduce antibiotic use by more than 20 per cent, according to a 2024 study in Vaccine.

    In fact, a 2020 study in Nature found that improving childhood vaccination coverage in low- and middle-income countries could reduce antibiotic-treated illnesses in kids under five by more than 20 per cent. That’s a massive step forward in the fight against antibiotic resistance.

    A wake-up call

    The measles outbreaks in Ontario and Alberta aren’t just local issues; they are a global warning. Each missed vaccine doesn’t just put one person at risk; it potentially means more infections, more complications and more antibiotics. That, in turn, means more antibiotic resistance for everyone.

    Vaccines are not just about individual protection. They are a public health strategy that keeps antibiotics effective for when we really need them, especially for vulnerable people like cancer patients, transplant recipients and the elderly, who rely on antibiotics to survive routine infections.

    Vaccines, in fact, do more than prevent disease. They protect our ability to treat infections by reducing the need for antibiotics and slowing the rise of resistant bacteria. With preventable diseases like measles making a comeback, now is the time to recognize the broader impact of vaccine hesitancy.

    Choosing to vaccinate is more than a personal decision. It’s a way to protect our communities and preserve the life-saving power of antibiotics for generations to come.

    Ruchika Gupta does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

    ref. How falling vaccination rates are fuelling the antibiotic resistance crisis – https://theconversation.com/how-falling-vaccination-rates-are-fuelling-the-antibiotic-resistance-crisis-259682

    MIL OSI Analysis

  • MIL-OSI United Kingdom: The MHRA and the global flu vaccine: How the UK is helping shape the world’s flu vaccine 

    Source: United Kingdom – Government Statements

    News story

    The MHRA and the global flu vaccine: How the UK is helping shape the world’s flu vaccine 

    Ensuring the seasonal flu vaccine is ready, safe and effective involves months of international planning, testing and collaboration

    Each year, millions of people across the globe catch influenza, commonly known as the flu. While many recover quickly, flu can be deadly, particularly for older adults, young children, and those with weakened immune systems. In the UK alone, seasonal flu can cause thousands of deaths in a bad year. This is why having an effective and up-to-date flu vaccine is crucial. 

    Millions of people around the world prepare for seasonal influenza by getting vaccinated. It’s something many of us take for granted – a quick injection at the GP or pharmacy. But behind the scenes, ensuring that vaccine is ready, safe, and effective involves months of international planning, testing, and collaboration. 

    At the heart of that global effort is the Medicines and Healthcare products Regulatory Agency (MHRA) – the UK’s regulator for medicines and medical devices. The MHRA’s role goes far beyond approving medicines for the UK. It also leads on the international stage by hosting the MHRA Global Influenza Meeting, a key event that helps guide the development and delivery of the world’s flu vaccines. 

    Why the flu vaccine needs updating every year 

    Unlike some viruses, like measles, the influenza virus constantly changes and evolves. This means that last year’s vaccine may not protect against this year’s strains. Each year, scientists and regulators across the world work together to track the latest strains of the virus and decide which ones should be included in the next season’s vaccine. 

    The World Health Organization (WHO) leads this process through a network of research centres and laboratories known as Global Influenza Surveillance and Response System. However, transforming that scientific research and development into safe, effective, and timely licensed vaccines involves regulators. The MHRA plays a key role in both aspects. 

    A meeting 20 years in the making 

    This year marks the 40th MHRA influenza meeting, held twice a year for the past 20 years. This year, it was held last week. What began as a European-focused gathering has grown into a major global event, drawing together public health experts, scientists, manufacturers, and regulators from across the world. 

    As Dr Othmar Engelhardt, the MHRA’s Head of Seasonal Influenza and organiser of the meetings, explains, the MHRA provides “a well-established venue for discussions within the community, bringing together everyone involved in the process of producing and delivering the vaccine after the strains relevant to a particular season are recommended by the WHO strain selection committee.” 

    What happens at the meeting? 

    The aim of the meeting is to ensure that all players have the information they need to ensure that the provision of the annual flu vaccine is the best it can be – delivered on time, with as few hurdles as possible. It’s a forum to share science, streamline processes, and keep the world prepared. 

    Topics covered are wide-ranging, including: 

    • Update on influenza in the world: Which flu viruses are circulating globally, and which are most likely to pose a threat in the coming season? 

    • Reagents and standards: What laboratory materials are available for testing and manufacturing? How can the community help speed up access to these materials? 

    • Vaccine production updates: How ready are manufacturers for the upcoming flu season following the WHO strain recommendation, and what’s needed to smooth the supply chain? 

    Importantly, there is also a focus on zoonotic influenza – flu viruses that jump from animals, such as birds or pigs, to humans. These have the potential to spark the next influenza pandemic, so surveillance and preparation of potential vaccine candidates are essential. 

    The disappearance of B/Yamagata 

    One notable scientific development in recent years is the apparent disappearance of the B/Yamagata flu lineage since the COVID-19 pandemic. Previously, flu vaccines were quadrivalent, meaning that they contained four virus components (two A types and two B types). Now, many have moved to a trivalent vaccine, with only three components – a shift that required regulatory review and approval. 

    Special topics: new vaccines and testing methods 

    Day three of the meeting was dedicated to a special topic, namely a workshop on new vaccine platforms and targets for influenza. As technology evolves, researchers are exploring faster and potentially more effective ways to develop, test and produce vaccines – including using mRNA technology and exploring universal flu vaccines (i.e. a vaccine against most flu strains -which would not have to be changed between seasons). 

    Another key area is vaccine potency (i.e. dose) testing. The current gold-standard method, called Single Radial Immunodiffusion (SRD), was developed in the 1970s by the National Institute for Biological Standards and Control (NIBSC), now part of the MHRA. Though still recommended by the WHO, researchers are now working on faster and more flexible alternatives, supported by a working group that reports back into the MHRA meeting. 

    The 40th meeting also featured reflections from former NIBSC/MHRA staff who were key contributors to SRD methodology, underscoring the UK’s longstanding leadership in this space. 

    MHRA’s international role 

    As one of the four WHO Essential Regulatory Laboratories (ERLs) – alongside labs in the US, Japan, and Australia – the MHRA plays a unique role. Its Influenza Resource Centre (IRC) helps develop candidate vaccine viruses (CVVs), ships CVVs and reagents around the world, contributes scientific expertise to vaccine strain selection, prepares biological standards and reagents for use in vaccine manufacture and testing, and our regulatory colleagues advise on the global regulatory process. 

    This role also places the MHRA at the forefront of pandemic preparedness, including contributing to the WHO’s Pandemic Influenza Vaccine Preparedness framework. This involves all the above. staying alert to emerging zoonotic threats and ensuring the global community is ready to respond. 

    A diverse and united audience 

    What makes the MHRA Global Influenza Meeting especially valuable is its diversity. It brings together the WHO, regulators, researchers and manufacturers in one open forum. In a field as complex and fast-moving as influenza, open communication is vital. 

    As Othmar noted, “The flu field can be difficult because the viruses change all the time, meaning that the vaccines have to change as well.” The meeting provides a rare opportunity for all the key players to align their goals, share progress, and prepare together. 

    Why it matters to the UK and the world 

    Ultimately, the MHRA’s role in facilitating this global collaboration helps ensure that flu vaccines are timely, safe, and effective, not just in the UK but across the world. From setting scientific standards to hosting crucial conversations, the MHRA continues to play a central role in protecting global health. 

    For us in the UK, this means protection each winter. For the global community, it means stronger defences against one of the world’s most common infectious threats. 

    So next time you’re offered a flu vaccination, remember that behind that quick appointment lies a year of global planning, science, and collaboration – with a lot of this happening right here in the UK.

    Updates to this page

    Published 22 July 2025

    MIL OSI United Kingdom

  • MIL-OSI United Kingdom: New Executive Chair to strengthen government’s plan to unleash life sciences for a healthier, wealthier Britain

    Source: United Kingdom – Executive Government & Departments

    Press release

    New Executive Chair to strengthen government’s plan to unleash life sciences for a healthier, wealthier Britain

    Steve Bates OBE appointed to help champion research and innovation and the use of technology to transform health and grow the UK economy.

    • Industry leader Steve Bates OBE appointed as Executive Chair for the Office for Life Sciences.
    • Office for Life Sciences to report into Health, Science and Business departments, recognising the industry’s importance to the health and growth missions in the Plan for Change.
    • Appointment is immediate action on Life Sciences Sector Plan pledge to strengthen links between sector and government.

    Industry leader Steve Bates OBE has today (Tuesday 22 July) been appointed as Executive Chair of the Office for Life Sciences, the cross-Government unit that champions research, innovation and the use of technology to transform health and grow the economy across the UK.

    The Office for Life Sciences (OLS) will report directly into the Business Secretary in addition to the Health Secretary and Technology Secretary, recognising that driving economic growth and investment in this key sector will be a crucial part of the OLS agenda in support of the Plan for Change.

    The moves show the government is taking immediate action to deliver the Life Sciences Sector Plan, the ambitious blueprint for unleashing the UK’s circa £100 billion life sciences sector as a force for economic growth and bettering the nation’s health, in aid of the Plan for Change. Forming one of the 8 core pillars of the modern Industrial Strategy, the Plan sets out the government’s commitment to deepening its ties with the life sciences sector, and strengthening the Office for Life Sciences to do so.

    It builds on the positive momentum coming from recent successes for OLS, such as the recent £1 billion investment deal with BioNTech which the Office was instrumental in delivering, and backing for groundbreaking research like that supported by Our Future Health and UK Biobank, as well as its role in the up to £600 million investment to deliver a Health Data Research Service that will be unmatched globally – bringing the power of data to bear to unlock breakthroughs in the diagnosis and treatment of diseases.

    Steve Bates is a recognised industry figurehead, having led the UK BioIndustry Association as CEO since 2012. He sits on the UK Life Sciences Council, and was a founder member of the UK Government’s Vaccine Taskforce. Steve was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Sciences in 2020.

    Steve Bates OBE said:

    The UK is great at life sciences. Great science, growth finance, world leading entrepreneurs, agile regulators, and key health data assets, all network here within a sector focused industrial strategy.

    I know we can deliver global health outcomes and UK economic growth because we did so through the Vaccine Taskforce during COVID. I look forward to selling the sector’s great story to the globe. It’s a privilege to help life science businesses start, grow, scale and renew in the UK ecosystem to deliver economic growth, prosperity and health.

    Science and Technology Secretary Peter Kyle said:

    The life sciences sector plays a unique role, as a catalyst for both economic prosperity, and better health outcomes for people across the UK. Its ongoing success will be pivotal to both our Plan for Change, and our modern Industrial Strategy.

    It is only right that we draw upon the nation’s best talent and expertise to push this sector on to even greater heights, and to that end I am delighted that Steve will be joining us in these endeavours.

    Health and Social Care Secretary Wes Streeting said:

    We’re turning the UK into a life sciences powerhouse and harnessing the genius of our country’s greatest scientific minds.

    I know that Steve will bolster this mission and help make Britain the envy of the world when it comes to medical innovation.

    Under his leadership, I’m confident the Office for Life Sciences will continue to drive groundbreaking research and fulfil the Plan for Change’s goal to transform healthcare for patients across the country.

    Business and Trade Secretary Jonathan Reynolds said:

    We want to make the UK a life sciences superpower. That’s why we earmarked it as a priority sector in our modern Industrial Strategy, which sets out how we will back the industry to keep it at the forefront of global innovation.

    This single front door for industry to engage with government will be key to achieving our life sciences mission, as will appointing talented leaders like Steve – boosting the sector to deliver on our Plan for Change to grow the economy.

    The Office for Life Sciences is a Directorate of 120 civil servants, which drives policy and delivery in the Life Sciences sector, supporting the government’s ambitions on economic growth and improved health that sit at the heart of the Plan for Change. Currently overseen by the Health Secretary and Technology Secretary, it will now also have more formalised links into the Department for Business and Trade to support the government’s Industrial Strategy.

    In his new role, Bates will act as an ambassador both domestically and internationally for the UK life sciences sector. He will work across government and the wider public sector to ensure engagement with industry around policy and investment happens productively and at pace, working closely with all 3 Secretaries of State, providing support and expert advice as required. 

    The UK is already a global leader in life sciences, with the sector worth around £100 billion to the economy, and employing around 300,000 people. These moves show the government’s determination to immediately deliver on its goals for the sector, as laid out in the Life Sciences Sector Plan. Developed in close coordination with the Government’s 10 Year Health Plan, the Plan is a vision for doubling down on the sector’s strengths – turning cutting-edge research into real-world results: new treatments, faster diagnoses, and more lives saved. It’s about making sure breakthroughs happen here – and stay here – creating jobs, improving lives in every part of the country, and driving growth.

    Notes to editors

    Steve Bates’ appointment will further strengthen our expert leadership in life sciences, working with OLS Director Rosalind Campion.

    DSIT media enquiries

    Email press@dsit.gov.uk

    Monday to Friday, 8:30am to 6pm 020 7215 3000

    Updates to this page

    Published 22 July 2025

    MIL OSI United Kingdom

  • MIL-Evening Report: COVID, flu, RSV: how these common viruses are tracking this winter – and how to protect yourself

    Source: The Conversation (Au and NZ) – By Adrian Esterman, Professor of Biostatistics and Epidemiology, University of South Australia

    nimis69/Getty Images

    Winter is here, and with it come higher rates of respiratory illnesses. If you’ve been struck down recently with a sore throat, runny nose and a cough, or perhaps even a fever, you’re not alone.

    Last week, non-urgent surgeries were paused in several Queensland hospitals due to a surge of influenza and COVID cases filling up hospital beds.

    Meanwhile, more than 200 aged care facilities around Australia are reportedly facing COVID outbreaks.

    So, just how bad are respiratory infections this year, and which viruses are causing the biggest problems?

    COVID

    Until May, COVID case numbers were about half last year’s level, but June’s 32,348 notifications are closing the gap (compared with 45,634 in June 2024). That said, we know far fewer people test now than they did earlier in the pandemic, so these numbers are likely to be an underestimate.

    According to the latest Australian Respiratory Surveillance Report, Australia now appears to be emerging from a winter wave of COVID cases driven largely by the NB.1.8.1 subvariant, known as “Nimbus”.

    Besides classic cold-like symptoms, this Omicron offshoot can reportedly cause particularly painful sore throats as well as gastrointestinal symptoms such as nausea and diarrhoea.

    While some people who catch COVID have no symptoms or just mild ones, for many people the virus can be serious. Older adults and those with chronic health issues remain at greatest risk of experiencing severe illness and dying from COVID.

    Some 138 aged care residents have died from COVID since the beginning of June.

    The COVID booster currently available is based on the JN.1 subvariant. Nimbus is a direct descendant of JN.1 – as is another subvariant in circulation, XFG or “Stratus” – which means the vaccine should remain effective against current variants.

    Free boosters are available to most people annually, while those aged 75 and older are advised to get one every six months.

    Vaccination, as well as early treatment with antivirals, lowers the risk of severe illness and long COVID. People aged 70 and older, as well as younger people with certain risk factors, are eligible for antivirals if they test positive.

    Influenza

    The 2025 flu season has been unusually severe. From January to May, total case numbers were 30% higher than last year, increasing pressure on health systems.

    More recent case numbers seem to be trending lower than 2024, however we don’t appear to have reached the peak yet.

    Flu symptoms are generally more severe than the common cold and may include high fever, chills, muscle aches, fatigue, sore throat and a runny or blocked nose.

    Most people recover in under a week, but the flu can be more severe (and even fatal) in groups including older people, young children and pregnant women.

    An annual vaccination is available for free to children aged 6 months to 4 years, pregnant women, those aged 65+, and other higher-risk groups.

    Queensland and Western Australia provide a free flu vaccine for all people aged 6 months and older, but in other states and territories, people not eligible for a free vaccine can pay (usually A$30 or less) to receive one.

    RSV

    The third significant respiratory virus, respiratory syncytial virus (RSV), only became a notifiable disease in 2021 (before this doctors didn’t need to record infections, meaning data is sparse).

    Last year saw Australia’s highest case numbers since RSV reporting began. By May, cases in 2025 were lower than 2024, but by June, they had caught up: 27,243 cases this June versus 26,596 in June 2024. However it looks as though we may have just passed the peak.

    RSV’s symptoms are usually mild and cold-like, but it can cause serious illness such as bronchiolitis and pneumonia. Infants, older people, and people with chronic health conditions are among those at highest risk. In young children, RSV is a leading cause of hospitalisation.

    A free vaccine is now available for pregnant women, protecting infants for up to six months. A monoclonal antibody (different to a vaccine but also given as an injection) is also available for at-risk children up to age two, especially if their mothers didn’t receive the RSV vaccine during pregnancy.

    For older adults, two RSV vaccines (Arexvy and Abrysvo) are available, with a single dose recommended for everyone aged 75+, those over 60 at higher risk due to medical conditions, and all Aboriginal and Torres Strait Islander people aged 60+.

    Unfortunately, these are not currently subsidised and cost about $300. Protection lasts at least three years.

    The common cold

    While viruses including COVID, RSV and influenza dominate headlines, we often overlook one of the most widespread – the common cold.

    The common cold can be caused by more than 200 different viruses – mainly rhinoviruses but also some coronaviruses, adenoviruses and enteroviruses.

    Typical symptoms include a runny or blocked nose, sore throat, coughing, sneezing, headache, tiredness and sometimes a mild fever.

    Children get about 6–8 colds per year while adults average 2–4, and symptoms usually resolve in a week. Most recover with rest, fluids, and possibly over-the-counter medications.

    Because so many different viruses cause the common cold, and because these constantly mutate, developing a vaccine has been extremely challenging. Researchers continue to explore solutions, but a universal cold vaccine remains elusive.

    How do I protect myself and others?

    The precautions we learned during the COVID pandemic remain valid. These are all airborne viruses which can be spread by coughing, sneezing and touching contaminated surfaces.

    Practise good hygiene, teach children proper cough etiquette, wear a high-quality mask if you’re at high risk, and stay home to rest if unwell.

    You can now buy rapid antigen tests (called panel tests) that test for influenza (A or B), COVID and RSV. So, if you’re unwell with a respiratory infection, consider testing yourself at home.

    While many winter lurgies can be trivial, this is not always the case. We can all do our bit to reduce the impact.

    Adrian Esterman receives funding from the Medical Research Future Fund.

    ref. COVID, flu, RSV: how these common viruses are tracking this winter – and how to protect yourself – https://theconversation.com/covid-flu-rsv-how-these-common-viruses-are-tracking-this-winter-and-how-to-protect-yourself-261383

    MIL OSI AnalysisEveningReport.nz

  • MIL-OSI United Kingdom: The UK is committed to achieving our shared goals for sustainable development: UK National statement at the High-level Political Forum on Sustainable Development

    Source: United Kingdom – Government Statements

    Speech

    The UK is committed to achieving our shared goals for sustainable development: UK National statement at the High-level Political Forum on Sustainable Development

    Statement by Lord Collins of Highbury, Minister for Africa and the UN, at the High-level Political Forum on Sustainable Development.

    As we mark the 80th anniversary of the United Nations, the United Kingdom is committed to working with you to achieve our shared goals for sustainable development.

    With targets way off track, and five years to go, through the Pact for the Future, we have all committed to picking up the pace.

    So, we must implement the shared vision we set out at the Financing for Development in Seville.

    Harnessing the power of the private sector.

    Raising revenue from domestic taxation and tackling illicit finance.

    Making sure ODA plays a catalytic role.

    With a roadmap to address unsustainable debt.

    And the United Kingdom is championing innovative financing instruments, leveraging the City of London expertise.

    This is part of how we renew confidence in multilateralism itself, but we also need a system that is more efficient, coherent and resilient.

    That’s why, the UK is backing the Secretary General’s UN at 80 initiative, calling for the ambitious reform needed to build a development system fit for the future.

    We are transforming the UK’s approach.

    Prioritising climate and nature, health, humanitarian assistance, and making sure everyone feels the benefits, including women and girls.

    Improving the systems every country needs to invest in public services that make a difference in people’s lives.

    And protecting the health of people and economies from backing ambition on Non-Communicable Diseases, to pledging further support for the Global Alliance for Vaccines and Immunisation, and co-hosting the Global Fund replenishment alongside South Africa.

    The last few months alone have seen success spanning Seville to the UN Ocean Conference. 

    So, be it the General Assembly, or COP30 in Brazil, let us make the most of opportunities to build on that, so we get back on track towards meeting the Sustainable Development Goals, in the months and years ahead.

    Thank you.

    Updates to this page

    Published 21 July 2025

    MIL OSI United Kingdom

  • MIL-OSI Asia-Pac: Service suspension of Children Community Vaccination Centre and Private Clinic COVID-19 Community Vaccination Stations tomorrow

    Source: Hong Kong Government special administrative region – 4

    Attention duty announcers, radio and TV stations:

    Please broadcast the following as soon as possible and repeat it at suitable intervals:

         As the Hong Kong Observatory will issue Tropical Cyclone Warning Signal No. 8 tomorrow (July 20), the Government announced that the Children Community Vaccination Centre (CCVC) and Private Clinic COVID-19 Vaccination Stations (PCVSs) under the COVID-19 Vaccination Programme will remain closed tomorrow and their vaccination service will be suspended. 

         If the Tropical Cyclone Warning Signal No. 8 is cancelled before 1pm tomorrow, the CCVC and PCVSs will reopen and resume vaccination service two hours after the cancellation and they will operate until the normal closing time. 

         Affected persons can make a new vaccination appointment through the booking system on the website of the COVID-19 Vaccination Programme (booking.covidvaccine.gov.hk) after the scheduled time of the original booking.

    MIL OSI Asia Pacific News

  • MIL-OSI United Kingdom: New medicine to protect higher-risk babies from RSV

    Source: Scottish Government

    Single injection to help prevent the common winter virus.

    More babies who are born very prematurely will now be protected against the respiratory syncytial virus (RSV) with the introduction of a new single injection which lasts throughout the winter season.

    Following advice from the Joint Committee on Vaccination and Immunisation (JCVI), the single dose long-acting antibody medicine, nirsevimab (Beyfortus®) will replace the five monthly jabs which were previously offered to higher-risk infants between October and February.

    In addition, the existing programme for higher risk infants is being expanded to include very preterm infants, born before 32 weeks.

    Minister for Public Health Jenni Minto:

    “RSV can be life-threatening to babies born very early.

    “That is why I am pleased the single jab will be offered by all NHS Boards across Scotland from this September, helping to protect these high-risk infants over winter.

    “We will continue to work hard to protect Scotland’s most vulnerable groups against the respiratory illnesses which circulate throughout the colder months. Our various prevention programmes help reduce avoidable admissions to hospital and therefore the pressure on our NHS.”

    Dr Sam Ghebrehewet, Head of Vaccination and Immunisation at Public Health Scotland, said:

    “The last year has seen significant progress in efforts to protect those most vulnerable to RSV, including the introduction of the maternal RSV vaccine which is offered at 28 weeks of pregnancy and helps protect newborn babies from serious illness. Babies born prematurely are at highest risk of serious complications from RSV and we welcome this programme expansion, which will help to ensure that even more babies are protected during their most vulnerable early months.”

    BACKGROUND

    RSV can lead to life-threatening pneumonia and infant bronchiolitis, a lung infection.

    The current RSV maternal vaccine (for infant protection) is given at 28 weeks, so the expansion of the programme to all infants born before 32 weeks gives protection to those babies who are unlikely to benefit from maternal vaccination.

    The new injection for babies is the latest development in efforts to protect those most vulnerable to RSV and prevent unnecessary hospital admissions over the busy winter period. Last August, Scotland was the first nation in the UK to introduce another new RSV vaccine, Abrysvo, for pregnant women and older adults – more than 70% of eligible older adults took up the offer, leading to a Public Health Scotland study, published in the Lancet, showing a 62% reduction in RSV related hospitalisations among this group.

    MIL OSI United Kingdom

  • MIL-OSI United Kingdom: British Army troops partner with Kenya Defence Forces to offer free medical services to Laikipia and Samburu residents

    Source: United Kingdom – Executive Government & Departments

    World news story

    British Army troops partner with Kenya Defence Forces to offer free medical services to Laikipia and Samburu residents

    Exercise Haraka Serpent provided over 3,000 residents with preventive, diagnostic, and curative medical services, along with healthcare education.

    • The medical outreach provided vital medical services to communities living in Lokusero, Musul, Nosorai, Laresoro, Sereolipi, Archer’s Post, Suguroi, Mathira and Kanduturai who have limited access to medical diagnosis and treatment.

    • The team offered a range of healthcare services such as nutrition screening, maternal health services, ENT check-ups, family planning services, health education sessions, and voluntary counselling and testing for HIV and AIDS, cervical screening and children’s immunisations.

    Friday 18 July 2025: British Army medical troops provided free medical services to over 3000 residents of Laikipia and Samburu Counties in the month of July 2025 in partnership with the Kenyan Defence Forces, Samburu County Government, and Beyond Zero.

    Exercise Haraka Serpent delivered a comprehensive range of preventive, diagnostic, and curative medical services, along with healthcare education, across nine locations—three in Laikipia North, three in Laikipia West, and three in Samburu County.

    Additionally, 202 MMR conducted a Defence Engagement with the Kenya Defence Forces (KDF) at Kahawa Garrison in Nairobi. During this engagement, 202 MMR clinicians provided specialised training focused on austere pre-hospital treatment, fostering a valuable exchange of experiences and best practices with KDF troops.

    Speaking at the end of Exercise Haraka Serpent, Robert Mathews, from 202 Multi Role Medical Regiment, said:

    This has been an extremely challenging yet worthwhile exercise for our deployed medics. To come to Kenya and assist our host nation medical staff and the medical staff from the Kenyan Defence Forces in providing outreach health care to remote parts of Samburu and Laikipia Counties has been extremely rewarding.

    We have worked closely with Kenyan led teams and together we have treated over 3000 people, this has also been a great learning experience for my medics for the vast majority of whom this is their first time in Kenya.

    Kenya Defence Forces Nursing Officer, Lt. Brian Kiplimo, said:

    We had three objectives for the exercise: offering healthcare to the marginalised communities who are not able to easily access healthcare facilities, learning, and enhancing our co-operation with BATUK.  The learning objective saw 45 KDF personnel trained on medical readiness during operations especially of casualty care. Through the exercise, we have been able to share experiences and knowledge with BATUK which is vital for future cooperation.

    British High Commissioner to Kenya Neil Wigan, said:

    This is a powerful demonstration of our mutual partnership between Kenya and the UK.  Through this medical outreach, we’ve seen the very best of what our partnership can achieve – bringing vital healthcare to remote communities, sharing knowledge between our armed forces, and strengthening the bonds between our people. Kenya remains a vital strategic partner to the UK. We have a shared history—and more importantly, we have a shared future. We’re going far, together.

    The medical outreach provided vital medical services to communities living in Lokusero, Musul, Nosorai, Laresoro, Sereolipi, Archer’s Post, Suguroi, Mathira and Kanduturai who have limited access to medical diagnosis and treatment. The team offered a range of healthcare services such as nutrition screening, maternal health services, ENT check-ups, family planning services, health education sessions, and voluntary counselling and testing for HIV and AIDS, cervical screening and children’s immunisations.  Among those who turned up for the free medical care, many locals presented with respiratory tract conditions and received appropriate medication.

    Notes for editors:

    • 202 MMR is specially trained and equipped to provide an integrated healthcare system within a single unit by integrating Deployed Primary Healthcare, Pre-Hospital Emergency Care, Medical Evacuation and Deployed Hospital Care capabilities. MMRs provide improved tactical flexibility, agility, clinical continuity and credibility throughout the Operational Patient Care Pathway (OPCP); by combining traditional Field Hospital General Service Medical Regiment roles into a new type of medical unit, MMRs integrate medical capability at the lowest level.

    • Under an agreement with the Kenyan Government, up to six infantry battlegroups per year, including Haraka Serpent, carry out up to eight-week exercises in Kenya, in preparation to deploy on operations or assume high-readiness tasks.

    • British Army Training Unit Kenya is a permanent training support unit based in Nanyuki. BATUK runs a wide range of training events and exercises for British and Kenyan troops including infantry, artillery, logistics, engineering, and medical specialists.  Every exercise includes the completion of projects to support the local communities amongst which BATUK live and work.

    • Neil tweets @FCDONeilWigan

    • You can follow UK activity in Kenya on Facebook, Twitter and Instagram (@UKinKenya)

    Contact Joy Odero Joy Odero for more information.

    Updates to this page

    Published 18 July 2025

    MIL OSI United Kingdom

  • MIL-OSI Europe: Written question – Renewed EU strategy for vaccination and to tackle vaccine hesitancy – E-002818/2025

    Source: European Parliament

    Question for written answer  E-002818/2025
    to the Commission
    Rule 144
    Michalis Hadjipantela (PPE)

    The COVID-19 pandemic has led to a significant decline in vaccination rates and a resurgence of vaccine-preventable diseases in Europe and globally. This is exacerbated by increased vaccine hesitancy, misinformation and the influence of populist and anti-vaccination movements, including in major partner countries, which further erode public trust in science and institutions.

    In the light of these developments and the calls for a new EU immunisation strategy, can the Commission clarify:

    • 1.What steps it can take to develop and implement a renewed, comprehensive EU plan to increase vaccination coverage, set EU-wide life-course immunisation targets and restore public trust in immunisation?
    • 2.How it will support Member States in countering misinformation and vaccine hesitancy, including through targeted communication and behavioural science approaches?
    • 3.How can it ensure equitable access to vaccines across all Member States?

    Submitted: 10.7.2025

    Last updated: 17 July 2025

    MIL OSI Europe News

  • MIL-OSI Asia-Pac: Hong Kong’s COVID-19 activity declines to low level and private doctors will no longer be provided with free COVID-19 drugs

    Source: Hong Kong Government special administrative region – 4

    The Centre for Health Protection (CHP) of the Department of Health (DH) today (July 17) said that the recent periodic upsurge of COVID-19 in Hong Kong has ended, with relevant indicators declining to the low levels recorded before April this year. In view of the fact that COVID-19 has been managed in the same way as an upper respiratory tract illness and in response to the significant decrease in the demand for COVID-19 oral antiviral drugs, the special arrangement of providing free oral antiviral drugs to private doctors for prescribing to eligible patients, which has been in place during the pandemic, will be discontinued on July 29. The Government reminded the private doctors to make their own arrangements with the relevant drug dealer if they intend to provide patients with locally registered COVID-19 oral antiviral drugs. Meanwhile, the public medical service will continue to prescribe COVID-19 oral antiviral drugs to patients with clinical needs in accordance with the arrangement for general drugs.
     
    End of COVID-19’s periodic upsurge

    There was a drastic upsurge in the level of COVID-19 activity in Hong Kong since April of this year, reaching its peak in mid-May. According to the latest surveillance data (as of the week ending July 12), all indicators of COVID-19 activity have dropped back to the low levels recorded before April. For sewage surveillance, the per capita viral load of SARS-CoV-2 virus decreased from around 770 000 copy/litre in mid-May to around 140 000 copy/litre in the most recent week; the percentage of respiratory samples tested positive for the SARS-CoV-2 virus also dropped from a peak of 13.80 per cent to 2.53 per cent in the most recent week. 
     
    COVID-19 oral antiviral drugs
     
    COVID-19 has become a common respiratory viral infection. For the general public, symptoms of SARS-CoV-2 infections are generally mild. Meanwhile, the monthly average number of treatment courses of COVID-19 oral antiviral drugs prescribed by private doctors to eligible COVID-19 confirmed patients this year has dropped significantly compared to the past two years. Taking into account the above factors, the Government will end the special arrangement on July 29. This arrangement provided private doctors with free COVID-19 oral antiviral drugs for prescribing to eligible patients during the pandemic. Private doctors can still provide free prescriptions to eligible COVID-19 confirmed patients on or before July 28.
     
    The Government reminded private doctors that if they intend to provide patients with COVID-19 oral antiviral drug registered in Hong Kong, they can order them directly from the drug dealer, prescribe the drug to patients and charge them. Members of the public with clinical needs may continue to make appointments for general out-patient clinic (GOPC) services through the GOPC Telephone Appointment System or the “Book GOPC” function on the Hospital Authority’s (HA) one-stop mobile application “HA Go”. GOPCs under the HA will continue to prescribe the relevant drugs to eligible COVID-19 confirmed patients with clinical needs according to their treatment guidelines. For more details of the GOPC services, please visit the GOPC website: www.ha.org.hk/goto/gopc/en.
     
    During the COVID-19 pandemic, the Government has been providing two COVID-19 oral antiviral drugs, procured by the HA, to private doctors for free prescription to eligible COVID-19 confirmed patients with clinical needs since April 2022. This arrangement was intended to mobilise all available healthcare manpower, including private doctors, for anti-epidemic support during the raging epidemic. Private doctors who have registered with the Electronic Health Record Sharing System could request the provision of the COVID-19 oral antiviral drugs via a dedicated online platform. They must follow the relevant treatment guidelines set out by the HA and are not allowed to charge their patients any fees for the COVID-19 oral antiviral drugs. As of June 30 this year, approximately 200 000 treatment courses were prescribed by private doctors to eligible COVID-19 confirmed patients for free.
     
    Severe COVID-19 cases primarily affect the elderly, the children and individuals with underlying illnesses. Scientific data has conclusively proven that the COVID-19 vaccine is effective in minimising the risk of severe disease or death. Members of the public who have not received the initial dose of the COVID-19 vaccine (including infants and children) should get vaccinated timely. Those at high risk should receive a booster dose as soon as possible. For more information on COVID-19 vaccination, please visit COVID-19 Vaccination Programme webpage. Although the periodic upsurge of COVID-19 has ended, there has been an upward trend in local influenza activity in Hong Kong recently. Members of the public should remain vigilant and maintain stringent personal, environmental and hand hygiene at all times.

    MIL OSI Asia Pacific News

  • MIL-OSI Africa: Government to roll out Mpox vaccines as new cases are detected

    Source: Government of South Africa

    The Department of Health has announced a vaccination drive against Mpox disease, as the number of laboratory-confirmed cases is gradually increasing in the country.

    According to the department, the vaccination programme will primarily target the provinces most affected, which currently include Gauteng, Western Cape, and KwaZulu-Natal.

    Two new laboratory-confirmed cases were recorded – one in Gauteng and one in the Western Cape. 

    These cases involve a 32-year-old from Cape Town and a 45-year-old from Johannesburg, and both individuals have no history of travel.

    This brings to 10 the total number of confirmed cases since the beginning of 2025.

    “Vaccination helps to control the spread of this preventable and manageable disease, with vaccinated individuals being protected from becoming infected and from developing severe complications,” the statement read. 

    The department said vaccination can be accessed at some public health facilities, travel clinics and a few private providers in the selected provinces.

    Meanwhile, the department has urged people to be vigilant about the symptoms of Mpox. 

    Those who suspect they may be at risk of Mpox infection are advised to consult their nearest health facility or healthcare provider for screening and testing. They should also enquire about their eligibility for this life-saving vaccination.

    “Priority will be given to people at a higher risk of contracting the virus, including those who came into close contact with people who tested positive, people with multiple sexual partners and travellers going to areas where there is an outbreak of Mpox. Where indicated, vaccination will be offered to pregnant women and children older than two years.” 

    Mpox vaccine

    The department received approximately 10 500 doses of the mpox vaccine, Imvanex, as a donation from the Africa Centres for Disease Control. 

    This donation was made through the Access and Allocation Mechanism for Mpox to help combat the various outbreaks of Mpox across the African continent.

    The South African Health Products Regulatory Authority (SAHPRA) authorised the importation of this vaccine through a Section 21 process, which covers the sale and use of medicines not yet registered in South Africa. 

    The National Control Laboratory tested Imvanex samples to establish the vaccine’s safety and efficacy before its release to the South African market.

    “The vaccine was found to be safe and is well tolerated in most people. As with any vaccine, some individuals may experience mild to moderate side effects after vaccination. This is a normal sign that the body is developing some level of immunity to prevent the severity of the disease if infected,” the department said.

    Several countries, including the Democratic Republic of the Congo, Nigeria, Uganda, the United States, Canada and European countries have utilised the Mpox vaccine to control the spread of the disease. 

    Common side effects that might be experienced following immunisation include pain, redness, swelling and itching at the injection site, muscle pain, headache, nausea and fever. 

    However, the department said most side effects disappear on their own within a few days without treatment.

    These side effects can be managed by having enough rest, staying hydrated and taking medication to manage pain, if needed. 

    Individuals are encouraged to report any suspected side effects following immunisation directly to a healthcare professional or via the Med Safety App, which can be downloaded for free on an Android or IOS smartphone at https://medsafety.sahpra.org.za.

    The number of Mpox vaccine doses allocated to South Africa is limited, and quantities will be issued in a phased approach, prioritising outbreak hotspots and based on vaccine availability. 

    More information regarding mpox vaccination sites can be accessed at https://health.gov.za/wp-content/uploads/2025/07/2025-MPOX-VACCINATION-SITES.pdf. – SAnews.gov.za

    MIL OSI Africa

  • MIL-OSI USA: Video Release: Sen. Johnson Holds Hearing Entitled “Voices of the Vaccine Injured”

    US Senate News:

    Source: United States Senator for Wisconsin Ron Johnson
    WASHINGTON – Yesterday, U.S. Sen. Ron Johnson (R-Wis.), Chairman of the Permanent Subcommittee on Investigations, held a hearing entitled “Voices of the Vaccine Injured.” The Subcommittee heard from five witnesses who discussed vaccine injuries and two witnesses who discussed vaccine efficacy.
    “All of the witnesses presented powerful testimony and engaged in respectful discussion. I believe all of these stories needed to be told and listened to. I sincerely hope that the hearing helped to bridge the gap and demonstrate how to heal and unify our horribly divided nation,” Sen. Johnson said. 
    Clips of the witnesses’ testimonies can be found here. 
    Watch the full hearing here. 

    MIL OSI USA News

  • MIL-OSI USA: Chairman Mann Leads Subcommittee Hearing on Safeguarding U.S. Agriculture, Disease Prevention in Animal Health

    Source: United States House of Representatives – Representative Tracey Mann (Kansas, 1)

    WASHINGTON, D.C. – Today, Rep. Tracey Mann (KS-01), chairman of the House Agriculture Committee’s Subcommittee on Livestock, Dairy and Poultry, led a subcommittee hearing entitled “Safeguarding U.S. Agriculture: The Role of the National Animal Health Laboratory Network (NAHLN).” During the hearing, the Chairman underscored the vital role the National Animal Health Laboratory Network plays in mitigating foreign animal diseases like the Highly Pathogenic Avian Influenza, African Swine Fever, and New World Screwworm. 

    Chairman Mann also emphasized the role institutions like the Kansas Veterinary Diagnostic Laboratory and the National Bio and Argo-Defense Facility play in preventing animal diseases from spreading and highlighted the devastating impact the New World Screwworm would have on cattle producers in the Big First District and across the country if it reaches U.S. borders. The Chairman ended his questioning touting investments the One Big Beautiful Bill Act made into animal health research, strengthening the nation’s food supply chain and better positioning the United States to focus on disease prevention rather than outbreak control. 

    Excerpts:

    [Opening Statement as Prepared]: “Good morning and thank you all for joining us at today’s hearing. I am excited to chair this hearing of the House Agriculture Committee’s Subcommittee on Livestock, Dairy, and Poultry, where we will focus on the important work of the National Animal Health Laboratory Network, or NAHLN. As a fifth-generation Kansas farm kid I grew up riding pens and doctoring cattle at my family’s preconditioning feedlot and I intimately understand the vital role that animal health plays in all livestock and poultry operations. 

    The National Animal Health Laboratory Network is a critical piece of our ability to respond to and mitigate foreign animal diseases. Originally comprised of 12 laboratories when created in 2002, the NAHLN network has grown to include over 60 State and university laboratories, including the Kansas State Veterinary Diagnostic Laboratory in Manhattan, Kansas.  

    These labs are strategically placed across the United States to support animal agriculture by developing and increasing the capabilities and capacities to support early detection, rapid response, and appropriate recovery from high-consequence animal diseases. Put simply, they are our first line of defense. 

    These labs do not operate in a vacuum. The NAHLN network is successful because of partnerships between Federal, State, and university-associated animal health laboratories and experts. This partnership is critical to response efforts when foreign animal diseases are detected, such as Highly Pathogenic Avian Influenza, New World Screwworm, African Swine Fever, and so many more.  

    Today, you will hear from a panel of experts who work at NAHLN laboratories. These experts will be able to share pertinent information about the critical work they do – whether it be tracking the New World Screwworm outbreak in Mexico, identifying the move of hi-path into dairy cattle in Texas, working with the National Bio and Agro-Defense Facility in Kansas, or crucial swine testing in Iowa. 

    This hearing could not come at a better time to highlight the work of the NAHLN laboratories and talk about the need for additional resources. As of two weeks ago, funding for NAHLN – as well as funding for the National Animal Disease Preparedness and Response Program and National Animal Vaccine and Veterinary Countermeasures Bank – was substantially increased in the One Big Beautiful Bill. 

    The One Big Beautiful Bill included $233 million per year for the three-legged stool, with $10 million per year directed towards the NAHLN laboratories, which is on top of existing discretionary funding. This funding will increase diagnostic capabilities, improve research, assist in disease surveillance, and strengthen our overall capacity as a nation to prevent, detect, and mitigate foreign animal diseases. I am proud of the work this Committee did to shore up our animal health resources and protect the herds and flocks that bring so much value to our producers and national security. 

    I look forward to hearing from our witnesses about the work they do, day in and day out, in their roles with the National Animal Health Laboratory Network. I am excited to hear about how the increased funding will help their operation of these laboratories, which foreign animal diseases they see as the most consequential, and how we as Congress can be good partners to them. Again, thank you all for being here.” 

    [On NBAF and NAHLN combatting foreign animal disease]: “The National Bio and Agro-Defense Facility in Manhattan, Kansas, is a state-of-the-art facility that will help protect the nation’s agriculture, farmers, and consumers against the threat and potential impacts of serious foreign animal diseases. NBAF has biosafety level 2, 3, and 4 laboratories, allowing them to study and diagnose the most consequential animal pathogens. NBAF plays a critical role in our animal disease preparedness and management and is an important partner to the NAHLN system. Dr. Retallick, how does the Kansas State Veterinary Diagnostic Laboratory collaborate with NBAF, and how will each of your operations supplement one another?” 

    Retallick: “We are excited to have NBAF as our neighbor in Manhattan, KS. NBAF has multiple missions, one of those is research and one of those is service, which is the NAHLN lab that was discussed. And so the NAHLN being a network, our interaction with them through the NAHLN and confirmatory testing is going to be the same as all the NAHLN laboratories for that. The other thing you might see us assist in NBAF is training the future technicians for them. Often entry level will come in, we will train, and they may go to work in NBAF. Ultimately, the collaboration will be very similar among all of the state laboratories, with NBAF being our parent lab and our confirmatory testing place.”

    [On New World Screwworm]: “The detection of New World Screwworm in Mexico is a huge threat to our domestic cattle producers. USDA estimates that a contemporary outbreak in Texas alone could cost producers $732 million per year. If you expand those results to the states within the historic range of New World Screwworm pre-eradication, a contemporary outbreak would cost producers as much as $4.3 billion per year and cause a total economic loss of over $10 billion. These are not losses our producers, or our economy, can afford. Again for you Dr. Retallick, surveillance and testing capacity was critical to eradicating this pest back in the 1960s. How are the NAHLN laboratories involved in preventing the spread of screwworm, and what role would they play if the pest were to reach our shores?”

    Retallick: As I stated earlier the NAHLN labs, many of them are in universities and state departments of ag, which have specialists. Each specialist is highly trained to recognize diseases and new disease threats. At KVDL, like many of the other labs in the network, we have parasitologists and pathologists who have already gone through training to recognize this. So, we will recognize through there. The NAHLN is also discussing it in their weekly calls, updating us and providing training. And in addition, with the caseload that comes through these diagnostic laboratories in the states, we see all sorts of things and animals for disposal, allowing us a large caseload to surveil coming in through routine testing.”

    [On One Big Beautiful Bill Act]: “Two weeks ago the One Big Beautiful Bill was signed into law. We were able to secure historic investments to modernize the farm safety net, promote ag products overseas, increase research, and important to this hearing, shore up our animal health tools. Under the One Big Beautiful Bill Act, the NAHLN system will receive $10 million annually through fiscal year 2030 on top of existing discretionary funding. At a time when foreign animal diseases are threatening our producers on all fronts, how will this investment help your lab to prepare for and respond to an outbreak?”

    Main: “Thank you. It would be a tremendous help, I would say, from providing a base of capacity and capability which is principally driven by our people. And that additional funding will enable I think, across the laboratory to really help with, I would say, maintaining adequate preparedness, via the people in the laboratory.

    ###

     

    MIL OSI USA News